Merck shared biopsy data for its MASH program after its dual GLP-1/glucagon agonist cleared a mid-stage trial, using data licensed from Hanmi Pharmaceutical. At #AASLD26, Merck’s presentation highlighted liver biopsy information tied to the Phase 2 MASH readout for the therapy it acquired under a 2020 licensing agreement worth $10 billion. The dataset is intended to support the company’s ongoing clinical strategy in a crowded liver-disease field where histology-based endpoints drive next-step decisions. The development places emphasis on how combined metabolic pathway modulation performs at tissue level, not just through noninvasive markers.